ART has averted over 850,000 HIV-related opportunistic infections in low and middle income countries
Combination inhibitor BMS-986197 demonstrates good activity against HIV in early study
Starting HIV therapy associated with improvements in liver function, especially when viral load is suppressed
High sexually transmitted infection rates among men on PrEP supports more frequent monitoring
HIV-related factors increase risk of stroke
Sofosbuvir/velpatasvir for hepatitis C can be administered with most antiretrovirals
Transgender people are at high risk for HIV, but too little is known about prevention and treatment for this population
Rapid rise in PrEP awareness in US gay men, but only 5% have used PrEP
Indiana HIV epidemic among people who inject drugs is controlled, but ongoing vigilance is needed
